Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.41 |
| ▸ | APEX1 | P27695 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113400 | 0.89 | ACHE (0.39) | HTR2CAPEX1HTR2AHTR2BASIC3 | |
| SCHEMBL30050918 | 0.78 | APEX1 (0.60) | HTR2CAPEX1HTR2AHTR2BADRB1 | |
| SCHEMBL18128899 | 0.78 | APEX1 (0.60) | HTR2CAPEX1HTR2AHTR2BADRB1 | |
| SCHEMBL29386754 | 0.78 | APEX1 (0.60) | HTR2CAPEX1HTR2AHTR2BADRB1 | |
| SCHEMBL14067586 | 0.77 | ACHE (0.38) | HTR2CACHE | |
| SCHEMBL19089065 | 0.75 | APEX1 (0.42) | APEX1TERT | |
| SCHEMBL21955684 | 0.75 | APEX1 (0.42) | APEX1TERT | |
| SCHEMBL4359812 | 0.75 | — | — | |
| SCHEMBL12691712 | 0.74 | CXCR4 (0.60) | HTR2CHTR2AADRB1 | |
| SCHEMBL27351093 | 0.74 | APEX1 (0.46) | HTR2CAPEX1HTR2AADRB1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | HTR2C 4084/4885APEX1 2397/4885HTR2A 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.